Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world treatment patterns, patient characteristics, and outcomes of cbtki-based therapies amongst a contemporary cohort of patients with R/R MCL in the United States

View Full Paper
Ask AI
Bookmark
Share

Authors

KMKami J. MaddocksMTMarsha TraceyDHDan He

Discussion

Loading...

Member takes

Overview

Observational analysis revealed poor outcomes in patients with R/R mantle cell lymphoma, suggesting a need for improved therapies.

Key Points

  • Patients with relapsed/refractory mantle cell lymphoma displayed high-risk disease characteristics during treatment initiation.
  • Overall median time-to-tx-discontinuation was 8.0 months, with significant variability based on therapy lines.
  • Kaplan-Meier analysis indicated that time-to-next-therapy was also poor, averaging 10.8 months across the cohort.
  • The study underscored the limited survival outcomes for patients, particularly those receiving advanced therapies.

Cite This Study

Maddocks et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d477https://doi.org/10.1182/blood-2025-2725
View Full Paper
Ask AI
Bookmark
Share